HIGH SPRINGS, FL--(Marketwire - March 08, 2010) - CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) today announced its plans to move the company’s Aquaplex® product line out of the CTD, Inc. division and into NanoSonic Products, Inc. (NSP). The decision was made as a result of a successful orphan drug application filing made to the U.S. Food and Drug Administration for Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin) in the treatment of Niemann Pick Type C disease.
Niemann Pick Type C disease is a rare, fatal illness caused by a genetic mutation, which prevents cholesterol and other lipids from properly metabolizing within the cell. As a result, dangerous amounts of cholesterol accumulate in the liver and spleen and ultimately the brain. Although rare, Niemann Pick Type C disease has generated enormous medical interest because a specific gene can now be associated with cholesterol homeostasis at the cellular level. In animal studies, parenteral use of Trappsol® Cyclo™ has been shown to restore cholesterol homeostasis in certain somatic and brain cells.
“This move allows CTD to focus its efforts on servicing the Trappsol® Cyclo™ needs of the research and medical community who are studying and treating Niemann Pick Type C disease,” said Rick Strattan, Chairman and CEO of CTD Holdings, Inc. “In addition, we are expanding our efforts as Cyclo™ may have efficacy in other cholesterol dyshomeostasis diseases, like Alzheimer’s, CAD, and Diabetes.”
“It could take up to 60 days for the FDA to make a decision to designate Trappsol® Cyclo™ an orphan dug product,” added Strattan. “We are cautiously optimistic that FDA approval based on the promising data that has been submitted will be forth coming and expect the filing to generate more inquires and requests for this remarkable compound.”
On March 1, 2010 the sales of Aquaplex® products were transferred to NanoSonic Products, Inc. (NSP), a newly formed division of CTDH. Dr. Jeffrey Tate, President and COO of NSP, remarked,” Planning and design of our c-GMP production facility is nearly complete and the first key pieces of manufacturing equipment have been specified and ordered. The revenue from current and future sales of Aquaplex® products will be invested in this expanded manufacturing capacity to further grow the sales volume.”
About CTD Holdings, Inc.
The company is the one-stop shop, business-to-business facilitator of commercial and research applications of Cyclodextrins. With its branded Trappsol®, Aquaplex® and Cyclo™ product offerings, CTDH scientists coordinate the development of commercial products for use in many diverse industries that endeavor to put non water-soluble ingredients into water-based formulations for direct use or conversion into stable, easy to use powders.
This news release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH is timely in the filing of its SEC mandated financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.
Contact:
Rick Strattan
386-454-0887
Email Contact